Last Updated : May 10, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Ngenla | somatrogon | Growth hormone deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
| Myinfla | colchicine | Atherothrombotic events in coronary artery disease | Do not reimburse | Complete | ||
| Opdivo | nivolumab | Gastroesophageal junction or esophageal adenocarcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Darzalex | daratumumab | Light chain (AL) amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Brukinsa | zanubrutinib | Waldenström’s macroglobulinemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Waymade-Trientine | trientine hydrochloride | Wilson's Disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Adtralza | tralokinumab | atopic dermatitis | Do not reimburse | Complete | ||
| Ultomiris | ravulizumab | Paroxysmal nocturnal hemoglobinuria | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | pembrolizumab | Classical Hodgkin lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opsynvi | macitentan and tadalafil | Pulmonary arterial hypertension | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 10, 2024